DRIO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.225

Open

7.070

VWAP

6.95

Vol

31.82K

Mkt Cap

51.77M

Low

6.550

Amount

221.19K

EV/EBITDA(TTM)

--

Total Shares

7.31M

EV

63.35M

EV/OCF(TTM)

--

P/S(TTM)

1.70

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

Show More

Events Timeline

(ET)

2026-07-06

08:00:00

DarioHealth Enters Agreement with Major Health Insurer

2026-07-02 (ET)

2026-07-02

08:00:00

DarioHealth Expands Partnership with Major U.S. Health Insurer

2026-06-29 (ET)

2026-06-29

07:30:00

DarioHealth Enters Collaborative Agreement with Beluga Health

2026-05-13 (ET)

2026-05-13

06:40:00

Dario Reports Q1 Revenue of $5.58M, Exceeding Expectations

2026-04-08 (ET)

2026-04-08

13:00:00

DarioHealth Trading Halted Due to Volatility

2026-03-19 (ET)

2026-03-19

06:40:00

Dario Signs 85 New Agreements in 2025, Expected Revenue of $12.9 Million in 2026

News

PRnewswire

07-06PRnewswire

DarioHealth Partners with Major Insurer to Expand Digital Health Solutions

Newsfilter

07-06Newsfilter

DarioHealth Partners with Major Insurer to Expand Digital Health Solutions

PRnewswire

07-02PRnewswire

DarioHealth Expands Health Plan Partnership

Newsfilter

07-02Newsfilter

DarioHealth Expands Health Plan Partnership

PRnewswire

06-30PRnewswire

DarioHealth Appoints Sean O'Reilly to Advisory Board to Enhance Strategic Growth

Newsfilter

06-30Newsfilter

DarioHealth Appoints Sean O'Reilly to Advisory Board to Enhance Strategic Growth

2 Analyst Rating

Wall Street analysts forecast DRIO stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

11.00

Averages

13.50

High

16.00

Current: 0.000

Low

11.00

Averages

13.50

High

16.00

Stifel

Buy

downgrade

$16 -> $10

AI Analysis

2026-03-20

Reason

Stifel

Price Target

$16 -> $10

AI Analysis

2026-03-20

downgrade

Buy

Reason

Stifel lowered the firm's price target on DarioHealth to $10 from $16 and keeps a Buy rating on the shares. The firm continues to model 2025 and 2026 revenue and EBITDA estimates below consensus as visibility on timing of the signing and ramp of contracts remains limited, adding that the stock is "unlikely to regain momentum until there is better visibility on revenue growth acceleration and achieving profitability."

Stifel

David Grossman

Buy

maintain

$16

2025-11-14

Reason

Stifel

David Grossman

Price Target

$16

2025-11-14

maintain

Buy

Reason

Stifel analyst David Grossman adjusted the firm's price target on DarioHealth to $16 from $1.25 and keeps a Buy rating on the shares. While "encouraged" by management's ability to lower expenses and continue to sign meaningful new customer relationships, the firm views the stock as unlikely to regain momentum until there are visible signs of accelerating revenue growth and a path to profitability. Following the 20-1 reverse stock split, the firm notes that its prior price target of $1.25 would have equated to $25.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DRIO

Unlock Now

Valuation Metrics

The current forward P/E ratio for DarioHealth Corp (DRIO.O) is 10.59, compared to its 5-year average forward P/E of -0.60. For a more detailed relative valuation and DCF analysis to assess DarioHealth Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.60

Current PE

10.59

Overvalued PE

3.04

Undervalued PE

-4.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.52

Current EV/EBITDA

-1.33

Overvalued EV/EBITDA

-1.41

Undervalued EV/EBITDA

-3.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.09

Current PS

1.37

Overvalued PS

5.44

Undervalued PS

0.73

Financials

AI Analysis

Annual

Quarterly

Whales Holding DRIO

Trading Trends

People Also Watch

Frequently Asked Questions

What is DarioHealth Corp (DRIO) stock price today?

The current price of DRIO is 7.08 USD — it has decreased -1.26

What is DarioHealth Corp (DRIO)'s business?

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

What is the price predicton of DRIO Stock?

Wall Street analysts forecast DRIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRIO is13.50 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is DarioHealth Corp (DRIO)'s revenue for the last quarter?

DarioHealth Corp revenue for the last quarter amounts to 5.58M USD, decreased -17.30

What is DarioHealth Corp (DRIO)'s earnings per share (EPS) for the last quarter?

DarioHealth Corp. EPS for the last quarter amounts to -1.25 USD, decreased -56.45

How many employees does DarioHealth Corp (DRIO). have?

DarioHealth Corp (DRIO) has 160 emplpoyees as of July 08 2026.

What is DarioHealth Corp (DRIO) market cap?

Today DRIO has the market capitalization of 51.77M USD.